GlassScriptPhysician profile
Heidi Heal
NPI 1912967498
$5,214.22
in general payments reported to CMS, 2019-2025
26 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $98.98 · 2022: $608 · 2023: $883 · 2024: $1,383 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,402 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.16 |
| Education | $104.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,815.72 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $677.17 | 2022-2025 | |
| Glaxosmithkline, LLC. | $645.41 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $376.49 | 2022-2025 | Dupixent |
| Alk-Abello, INC | $188.68 | 2022-2025 | Grastek, Odactra |
| Ars Pharmaceuticals Operations, INC. | $164.53 | 2025 | Neffy |
| Kaleo, INC. | $149.57 | 2023-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $142.63 | 2021-2024 | Cuvitru, Hyqvia |
| Csl Behring | $142.59 | 2024-2025 | Hizentra |
| Amgen INC. | $124.38 | 2022-2025 | Tezspire, Actimmune |
| Optinose US, INC. | $113.13 | 2022-2025 | |
| Pharming Healthcare, INC. | $99.79 | 2024-2025 | Ruconest |
| Grifols USA, LLC | $93.49 | 2023-2024 | Xembify |
| Pfizer INC. | $75.59 | 2025 | |
| Novartis Pharmaceuticals Corporation | $65.13 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $62.54 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.52 | 2021-2023 | |
| Leo Pharma INC. | $38.82 | 2025 | Adbry |
| Genentech USA, INC. | $32.50 | 2024 | Xolair |
| Bio Products Laboratory USA, INC. | $27.05 | 2022 | |
| Octapharma USA, INC. | $24.73 | 2023 | Cutaquig |
| Kowa Pharmaceuticals America, INC. | $22.84 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $22.08 | 2022 | |
| Incyte Corporation | $22.08 | 2025 | Opzelura |
| Phadia US INC. | $17.98 | 2024 | Immunocap |
| Paratek Pharmaceuticals, INC. | $15.78 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Heal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.